NOLUDAR
LOE ApproachingNDAORALELIXIR
Approved
Jan 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NOLUDAR is an oral elixir small-molecule drug developed by Roche and approved in 1955. The mechanism of action and therapeutic indication are not publicly detailed in available records. This legacy product represents a foundational era of pharmaceutical development.
LOE Approaching
As a legacy product approaching loss of exclusivity with minimal linked job activity, this asset likely operates with a small, maintenance-focused commercial team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NOLUDAR offers limited career growth potential as a legacy product with zero linked job openings and approaching loss of exclusivity. Roles on this asset are primarily maintenance-oriented, focused on defending market position rather than growth or innovation.
Brand Manager (legacy/maintenance)Medical Science Liaison
Worked on NOLUDAR at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.